One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Keratinocytes: wolves in sheep’s clothing
Jessica McHugh
doi : 10.1038/s41584-020-00569-9
Volume 17, Issue 2, February 2021, Published 05 January 2021
Regulatory eosinophils to the rescue
Joanna Clarke
doi : 10.1038/s41584-020-00564-0
Volume 17, Issue 2, February 2021, Published 14 December 2020
Targeting Kv1.3 channels on T cells
Ellen F. Carney
doi : 10.1038/s41584-020-00560-4
Volume 17, Issue 2, February 2021, Published 09 December 2020
Spectrum and impact of checkpoint inhibitor-induced irAEs
Laura C. Cappelli & Clifton O. Bingham III
doi : 10.1038/s41584-020-00546-2
Volume 17, Issue 2, February 2021, Published 24 November 2020
Immune checkpoint inhibitors, which are used to treat many types of cancer, can cause syndromes similar to rheumatic diseases known as immune-related adverse events (irAEs). In 2020, several studies illustrated the clinical heterogeneity of rheumatic irAEs and highlighted their substantial effect on morbidity and mortality.
Rheumatic disease and COVID-19: epidemiology and outcomes
Kimme L. Hyrich & Pedro M. Machado
doi : 10.1038/s41584-020-00562-2
Volume 17, Issue 2, February 2021, Published 18 December 2020
Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have been identified. Whether patients with rheumatic diseases, especially those receiving DMARDs, are at an increased risk of SARS-CoV-2 infection or severe COVID-19 disease remains unclear, although epidemiological studies are providing some insight.
Switching on resolution to treat RA moves closer to reality
Mauro Perretti
doi : 10.1038/s41584-020-00549-z
Volume 17, Issue 2, February 2021, Published 30 November 2020
In inflammatory arthritides, such as rheumatoid arthritis (RA), synovial cells acquire aggressive and disruptive phenotypes that lead to joint disease. Three studies published in 2020 have described phenotypic variation in synovial cells, offering a novel perspective on the potential to resolve pathology and augment treatment options for patients with RA.
MIS-C: early lessons from immune profiling
Lauren A. Henderson & Rae S. M. Yeung
doi : 10.1038/s41584-020-00566-y
Volume 17, Issue 2, February 2021, Published 21 December 2020
Multisystem inflammatory syndrome in children (MIS-C) is a rare complication of SARS-CoV-2 infection that can result in serious illness in the paediatric population but our understanding of this syndrome is in its infancy. Translational studies in 2020 leveraging immune profiling have laid the foundation to enable further discovery in MIS-C.
New treatments for PsA meet targeted therapy goals
Philip J. Mease
doi : 10.1038/s41584-020-00561-3
Volume 17, Issue 2, February 2021, Published 16 December 2020
Interest in therapies for psoriatic arthritis (PsA) has increased in response to recognition that many patients remain undiagnosed and are inadequately treated. In 2020, advances in PsA treatments have included phase III trials of an IL-23 inhibitor, head-to-head trials of IL-17 inhibition against TNF inhibition and updated EULAR treatment guidelines.
New insights into the treatment of CTD-ILD
Athol U. Wells
doi : 10.1038/s41584-020-00567-x
Volume 17, Issue 2, February 2021, Published 06 January 2021
Interstitial lung disease (ILD) can arise in a variety of connective tissue diseases (CTDs) and various treatment interventions are being explored. In 2020, advances in the treatment of CTD-associated ILD have included the re-evaluation of methotrexate-induced lung injury and emerging insights on anti-IL-6 therapy and anti-fibrotic therapy in this condition.
Immunogenicity of biologic agents in rheumatology
Vibeke Strand, Joao Goncalves & John D. Isaacs
doi : 10.1038/s41584-020-00540-8
Volume 17, Issue 2, February 2021, Published 14 December 2020
The immunogenicity of a biologic agent can have clinical consequences in terms of response to therapy and risk of adverse events. In this Review, the authors summarize the latest data on the immunogenicity of biologic agents for various rheumatic indications.
Toll-like receptor signalling in B cells during systemic lupus erythematosus
Simon Fillatreau, Benoît Manfroi & Thomas D?rner
doi : 10.1038/s41584-020-00544-4
Volume 17, Issue 2, February 2021, Published 18 December 2020
Loss of B cell tolerance to autoantigens in systemic lupus erythematosus (SLE) is driven by TLR7, whereas TLR9 appears to protect against SLE by limiting the stimulatory activity of TLR7. The unique features of Toll-like receptor signalling in B cells implicate it as a therapeutic target in SLE.
Axial spondyloarthritis: concept, construct, classification and implications for therapy
Philip C. Robinson, Sjef van der Linden, Muhammad A. Khan & William J. Taylor
doi : 10.1038/s41584-020-00552-4
Volume 17, Issue 2, February 2021, Published 23 December 2020
In this Review, the authors examine how the definition and description of axial spondyloarthritis (axSpA) has evolved, most notably with the introduction of the concept of non-radiographic axSpA, and discuss the implications of these changes for diagnosis, classification and therapy.
Key opinion leaders — a critical perspective
Jose U. Scher & Georg Schett
doi : 10.1038/s41584-020-00539-1
Volume 17, Issue 2, February 2021, Published 30 November 2020
In this article, the authors critically appraise the current model of opinion-based academia–industry interactions, and advocate for a realignment towards partnerships that foster innovation and knowledge.
